COMMUNIQUÉS West-GlobeNewswire

Transactions in relation to share buyback program
26/12/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
NANOBIOTIX : 2017 review and 2018 expected milestones
26/12/2017
Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]
NANOBIOTIX : revue de l'année 2017 et perspectives 2018
26/12/2017
Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]
NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial
26/12/2017
FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]
NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix
26/12/2017
LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.
23/12/2017
Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD Positions Summit as a Leader in Research & Development [...]
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
23/12/2017
Positions Summit as a Leader in Research & Development of New Classes of Antibiotics Enhances Summit’s Broader Business in Rare and Infectious Diseases Supports Mission to Discover and Develop Therapies for Patients [...]
MedMira Reports First Quarter Results
23/12/2017
HALIFAX, Nova Scotia, Dec. 22, 2017 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSX-V: MIR ), reported today on its financial results for the quarter ended October 31, 2017. Profit and Loss Highlights Revenue: In Q1 [...]
Helius Medical Technologies Announces Closing of First Tranche of Private Placement
23/12/2017
NEWTOWN, Pa., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX: HSM ) (TSX:HSM.WT) (OTCQB:HSDT) (“Helius” or the “Company”) , a medical technology company focused on neurological wellness, is [...]
MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna
23/12/2017
PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a diagnostics company that enables the development and commercialization of precision medicines in oncology, announced [...]
Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel
22/12/2017
SAN FRANCISCO and TEL AVIV, Israel, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the " Company " or " Kalytera ") today announced that the TSX Venture Exchange (“ TSXV [...]
Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)
22/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that the U.S. Food and Drug Administration (FDA) will extend its review of the Biologics [...]
MPX Closes Oversubscribed Private Placement Offering of $26.5 Million
22/12/2017
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Dec. 22, 2017 (GLOBE NEWSWIRE) -- (CSE:MPX) (OTC:MPXEF) MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE: [...]
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22/12/2017
Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP Deep and sustained molecular response included as key eligibility criteria for attempting TFR after [...]
Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore
22/12/2017
CHARLESTON, S.C., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (the “Company” or “Aeterna Zentaris”) (NASDAQ: AEZS ) (TSX: AEZS ), a specialty biopharmaceutical company engaged in developing and [...]
ATW Tech Completes a Private Placement of Units of $423,640
22/12/2017
MONTREAL, Dec. 22, 2017 (GLOBE NEWSWIRE) -- AtmanCo inc. (“AtmanCo” or the “Company”) (TSX-V: ATW ) is pleased to announce the closing of a private placement consisting of the issuance of 3 530 333 units at a price of $ [...]
ATW Tech complète un placement privé d’unités de 423 640 $
22/12/2017
MONTRÉAL, 22 déc. 2017 (GLOBE NEWSWIRE) -- ATW Tech (« AtmanCo Inc. » ou la « Société ») (TSX CROISSANCE:ATW) annonce aujourd'hui la clôture d’un placement privé de 423 640 $ par l’émission de 3 530 333 unités au prix [...]
Abattis Provides Company Update and Comments on LOI Regarding Green Tree Therapeutics
22/12/2017
VANCOUVER, British Columbia, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to provide a company update and further commentary on its [...]
PSI Raises Record Amount for Charity at its 20th Annual Golf Tournament
22/12/2017
ARLINGTON, Va., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Planned Systems International, Inc. (PSI), a leading provider of Health IT solutions to the federal government, is pleased to announce that it raised a record for [...]

Pages